Navigation Links
AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
Date:5/20/2013

NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy.  The study will evaluate atrasentan's impact on renal outcomes, such as the onset of end-stage renal disease (ESRD), as defined by need for chronic dialysis, transplant or death due to renal failure progression.i

The initiation of the Phase 3 study follows results from Phase 2b studies, which were presented today during a late breaking clinical trials scientific session at the 2013 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Istanbul, Turkey.ii

"There is a pressing need for new medications to treat nephropathy in patients with type 2 diabetes, who have a high risk to end up in dialysis," said Dick de Zeeuw , M.D., Ph.D., Professor and Chair of the Department of Clinical Pharmacology and Department of Nephrology at the University of Groningen, the Netherlands, and Co-Chair of the SONAR steering committee. "Phase 2 studies of atrasentan in this patient population have shown encouraging results, and we look forward to further evaluating this investigational treatment in the Phase 3 SONAR study."

Diabetic nephropathy, or diabetic kidney disease, is a common complication of diabetes and the leading cause of CKD
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... Conn. , Oct. 22, 2014  Recently published ... have bolstered the already substantial database of evidence. This ... adoption of Stretta therapy for sufferers of ... clinical evidence supporting Stretta therapy as a ... policies that make Stretta therapy available to nearly 50 ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ... today that its abstract, entitled "Open,Label Study ... (PD) of Five Oral Insulin Formulations in ... the upcoming 44th Annual,Meeting of the European ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, will host a webcast and conference call ... Eastern Time (4:00 p.m. Central European,Time) to discuss ... Journal,SCIENCE on August 15, 2008., To access ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... named,Richard L. Wonsettler to the newly created position of ... Wonsettler, who has nearly 20 years of financial,management experience ... that Cohera Medical is preparing to enter the clinical ... "We are entering an important phase in the ...
... 30 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or ... a leading provider of,technology and pharmacy benefits management ... for its informedRx(R) pharmacy benefit management,("PBM") services with ... begin providing its services for more than 6,000 ...
... Response by End of Week -, LAVAL, ... DDS;,NASDAQ: DDSS) today announced that the Company has ... Administration (FDA) regarding its most recent,appeal of the ... once-daily,tramadol formulation through the Formal Dispute Resolution process., ...
... national investigation of the drug called Diditek. In April ... UDL Laboratories Digitek (digoxin tablets, USP, all strengths) for ... time many consumers or their families have received notification ... to talk to any consumer who took this drug ...
... new assistive technology developed by engineers at the ... severe disabilities lead more independent lives. , ... operate a computer, control a powered wheelchair and ... tongues. , "This device could revolutionize the field ...
... are twice as likely to develop rheumatoid arthritis in ... ahead of print in the Annals of the ... origin of disease theory, which argues that certain conditions ... during the pregnancy. , Diabetes, coronary heart disease, and ...
Cached Medicine News:Health News:Cohera Medical Names Richard L. Wonsettler as Company's First CFO 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 2Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 3Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 2Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 2Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 4
MONOJECT Red/Yellow Mottled Stopper...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Fluoride Tubes - Plastic...
Medicine Products: